• PDF / 169,318 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 10 Downloads / 129 Views

DOWNLOAD

REPORT

---

1

Daclatasvir/sofosbuvir Anaemia: case report In a retrospective observational study of 31 patients, a patient [age and sex not stated] was described, who developed anaemia during treatment with sofosbuvir and daclatasvir for hepatitis-C virus (HCV) infection. The patient, who had undergone renal transplant, presented with HCV infection. The patient subsequently started receiving direct acting antivirals therapy with sofosbuvir and daclatasvir [dosages and routes not stated]. Afterwards, the patient developed anaemia, which was suspected to be induced by sofosbuvir and daclatasvir [durations of treatments to reaction onset and outcome not stated]. Author comment: "[Direct antiviral agents] induced severe anaemia. . .occurrence of anaemia was. . .14.2% in sofosbuvir with daclatasvir therapy (n= 1)". Gandhi TS, et al. Direct antiviral agents in the treatment of hepatitis C virus infection in renal transplant recipients: A single centre experience. Indian Journal of Nephrology 28 (Suppl. 1): S15, No. 7, Dec 2018. Available from: URL: http:// www.indianjnephrol.org/temp/IndianJNephrol2871-4053121_111531.pdf [abstract] 803439301 - India

0114-9954/19/1783-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved

Reactions 14 Dec 2019 No. 1783